Luis Sargento1, Andre Vicente Simões2, Susana Longo3, Nuno Lousada3, Roberto Palma Dos Reis3. 1. Heart Failure Unit, Cardiology Department, Pulido Valente Hospital, Lisbon North Hospital Centre, Alameda Linhas de Torres, 1769-001, Lisboa, Portugal. luisjosesargento@gmail.com. 2. Department of Internal Medicine, Pulido Valente Hospital, Lisbon North Hospital Centre, Lisbon, Portugal. 3. Heart Failure Unit, Cardiology Department, Pulido Valente Hospital, Lisbon North Hospital Centre, Alameda Linhas de Torres, 1769-001, Lisboa, Portugal.
Abstract
BACKGROUND: Heart failure with reduced ejection fraction (HFrEF) is a disease of older people, but the target doses of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACEIs/ARBs) are unknown. OBJECTIVE: To evaluate the association of ACEI/ARB dose level with long-term survival in stable older patients (aged >70 years) and octogenarian outpatients with HFrEF. POPULATION AND METHODS: A total of 138 outpatients aged >70 years (35.5 % > 80 years), with an LVEF <40 % and who were clinically stable on optimal therapy were followed up for 3 years. The ACEI/ARB doses were categorized as: none (0), low (1-50 % target dose), and high (50-100 % target dose). The Cox regression survival model was adjusted for age, ischemic etiology, and renal function. RESULTS: ACEIs/ARBs were prescribed to 91.3 % of patients, and 52.9 % received the high dose. Survival improved with increasing ACEI/ARB dose level in the total population (Hazard Ratio [HR] = 0.67; 95 % confidence interval [CI] 0.55-0.82; p < 0.001), older patients aged >70 years (HR = 0.65; 95 % CI 0.51-0.83; p < 0.001), and octogenarians (HR = 0.71; 95 % CI 0.51-0.99; p = 0.045). The low (HR = 0.35; 95 % CI 0.16-0.76; p = 0.008) and high doses (HR = 0.13; 95 % CI 0.06-0.32; p < 0.001) improved survival compared with not receiving ACEIs/ARBs. The high dose was associated with a better survival than the low dose in the total population (HR = 0.35; 95 % CI 0.19-0.67; p = 0.001) and in a propensity score-matched cohort (HR = 0.41; 95 % CI 0.16-1.02; p = 0.056). In octogenarians, all dose levels were associated with improved survival compared with not receiving ACEIs/ARBs, but there was no difference between ACEI/ARB doses. CONCLUSION: The achieved optimal dose of ACEIs/ARBs in ambulatory older people with HFrEF is associated with long-term survival.
BACKGROUND:Heart failure with reduced ejection fraction (HFrEF) is a disease of older people, but the target doses of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACEIs/ARBs) are unknown. OBJECTIVE: To evaluate the association of ACEI/ARB dose level with long-term survival in stable older patients (aged >70 years) and octogenarian outpatients with HFrEF. POPULATION AND METHODS: A total of 138 outpatients aged >70 years (35.5 % > 80 years), with an LVEF <40 % and who were clinically stable on optimal therapy were followed up for 3 years. The ACEI/ARB doses were categorized as: none (0), low (1-50 % target dose), and high (50-100 % target dose). The Cox regression survival model was adjusted for age, ischemic etiology, and renal function. RESULTS: ACEIs/ARBs were prescribed to 91.3 % of patients, and 52.9 % received the high dose. Survival improved with increasing ACEI/ARB dose level in the total population (Hazard Ratio [HR] = 0.67; 95 % confidence interval [CI] 0.55-0.82; p < 0.001), older patients aged >70 years (HR = 0.65; 95 % CI 0.51-0.83; p < 0.001), and octogenarians (HR = 0.71; 95 % CI 0.51-0.99; p = 0.045). The low (HR = 0.35; 95 % CI 0.16-0.76; p = 0.008) and high doses (HR = 0.13; 95 % CI 0.06-0.32; p < 0.001) improved survival compared with not receiving ACEIs/ARBs. The high dose was associated with a better survival than the low dose in the total population (HR = 0.35; 95 % CI 0.19-0.67; p = 0.001) and in a propensity score-matched cohort (HR = 0.41; 95 % CI 0.16-1.02; p = 0.056). In octogenarians, all dose levels were associated with improved survival compared with not receiving ACEIs/ARBs, but there was no difference between ACEI/ARB doses. CONCLUSION: The achieved optimal dose of ACEIs/ARBs in ambulatory older people with HFrEF is associated with long-term survival.
Authors: Edward P Havranek; Frederick A Masoudi; Kelly A Westfall; Pam Wolfe; Diana L Ordin; Harlan M Krumholz Journal: Am Heart J Date: 2002-03 Impact factor: 4.749
Authors: Salim Bary Barywani; Constantinos Ergatoudes; Maria Schaufelberger; Max Petzold; Michael L X Fu Journal: Int J Cardiol Date: 2015-04-01 Impact factor: 4.164
Authors: Marcus D Flather; Marcelo C Shibata; Andrew J S Coats; Dirk J Van Veldhuisen; Aleksandr Parkhomenko; Joszef Borbola; Alain Cohen-Solal; Dan Dumitrascu; Roberto Ferrari; Philippe Lechat; Jordi Soler-Soler; Luigi Tavazzi; Lenka Spinarova; Jiri Toman; Michael Böhm; Stefan D Anker; Simon G Thompson; Philip A Poole-Wilson Journal: Eur Heart J Date: 2005-01-09 Impact factor: 29.983
Authors: Benjamin A Steinberg; Christopher P Cannon; Adrian F Hernandez; Wenqin Pan; Eric D Peterson; Gregg C Fonarow Journal: Am J Cardiol Date: 2007-08-13 Impact factor: 2.778
Authors: Marvin A Konstam; James D Neaton; Kenneth Dickstein; Helmut Drexler; Michel Komajda; Felipe A Martinez; Gunter A J Riegger; William Malbecq; Ronald D Smith; Soneil Guptha; Philip A Poole-Wilson Journal: Lancet Date: 2009-11-16 Impact factor: 79.321
Authors: Frederik H Verbrugge; Matthias Dupont; Philippe De Vusser; Maximo Rivero-Ayerza; Hugo Van Herendael; Jan Vercammen; Linda Jacobs; David Verhaert; Pieter Vandervoort; W H Wilson Tang; Wilfried Mullens Journal: Eur J Heart Fail Date: 2012-09-20 Impact factor: 15.534
Authors: Frederick A Masoudi; Edward P Havranek; Pam Wolfe; Cary P Gross; Saif S Rathore; John F Steiner; Diana L Ordin; Harlan M Krumholz Journal: Am Heart J Date: 2003-08 Impact factor: 4.749
Authors: Lin Li; Bill M Jesdale; Anne Hume; Giovanni Gambassi; Robert J Goldberg; Kate L Lapane Journal: J Card Fail Date: 2017-09-20 Impact factor: 5.712
Authors: Michael J Diamant; Sean A Virani; Winston J MacKenzie; Andrew Ignaszewski; Mustafa Toma; Nathaniel M Hawkins Journal: ESC Heart Fail Date: 2019-06-20